Curanex Pharmaceuticals Inc (CURX) stock
CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.70−0.00 (-0.00%)
Close on Nov 18, 2026Market cap $7.37MP/E –Yield –
Curanex Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Curanex Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$12.43M. For fiscal 2025 it was -$4.24M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.24M | – |
| FY2024 | Dec 31, 2024 | -$365.06K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$2.83M | – |
| Q2 FY2026 | Jun 30, 2026 | -$3.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.18M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.09M | – |
| Q3 FY2025 | Sep 30, 2025 | -$951.33K | – |
| Q2 FY2025 | Jun 30, 2025 | -$57.66K | – |
| Q1 FY2025 | Mar 31, 2025 | -$137.45K | – |
| Q4 FY2024 | Dec 31, 2024 | -$147.37K | – |
| Q3 FY2024 | Sep 30, 2024 | -$93.30K | – |
| Q2 FY2024 | Jun 30, 2024 | -$44.20K | – |
See a number that looks wrong?